Radiology

Guest: Tyler J Bradshaw, PhD In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more about these new technologies

Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.

Host: Jonathan D. Schoenfeld, MD, MPhil, MPH Guest: Robert L. Ferris, MD, PhD The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Joi

Host: Ezra Cohen, MD, FRCPSC, FASCO Guest: Sue S. Yom, MD, PhD The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are

Host: Neilanjan Nandi, MD Guest: Nicholas Shaheen, MD, MPH How do we determine which of our patients with Barrett's esophagus with dysplasia are good candidates for ablation therapy, and what’s the role of the gastroenterologist in serving patients who've already received post-ablative therapy? Joining Dr. Neil Nandi to answer those and other key questions is Dr. Nichola

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Emily Carroll, JD, MSW The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior l

Guest: Arlene B. Chapman, MD Guest: Matthew B. Lanktree, MD, PhD This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.

Guest: Jimmy T. Lee, MD Guest: Arlene B. Chapman, MD This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Nadia N. Laack, MD As survival for patients with pediatric brain tumors improves, reducing the long-term effects of cancer treatment is increasingly important. Fortunately, proton radiotherapy along with several other advancements are helping us achieve that goal. Here to share the latest treatments for pediatric patients wit

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Rajeev Attam, MD Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterolo